All News

The findings highlight the potential of field-effect-informed liquid biopsy methods to guide adjuvant treatment decisions in NMIBC.

David Morris, MD, FACS, highlights key strategies for counseling patients receiving the gemcitabine intravesical system as well as considerations for maintaining patients on therapy long enough to achieve meaningful clinical benefit.

ImmunityBio has submitted a formal response to the FDA and initiated corrective actions.

The following FAQ highlights key recommendations for urologists from the 2026 AUA Vasectomy Guideline.

In this episode of the UroOnc Minute, Wesley Yip, MD, joins host Adam B. Weiner, MD, to discuss key takeaways from LITESPARK-022, exploring the role for adjuvant pembrolizumab plus belzutifan in patients with clear cell renal cell carcinoma.

The code, J9183, may be used by physicians and treatment centers for billing and reimbursement beginning April 1, 2026.

"Urologists today are armed with 2 guideline-supported modalities to reduce the burden of unnecessary biopsies while maintaining timely detection of clinically significant cancers," write the authors.

A recap of the FDA submissions and regulatory decisions in urology from March 2026.

Take a look through the top 10 stories in urology from the past quarter.

A recap of the FDA approvals and clearances across urology from January through March.

The device will be available over the counter in the US, with anticipated availability beginning in April 2026.

At 3 years, transdermal estradiol demonstrated noninferior MFS compared with standard LHRH agonists.

The study is evaluating the safety, tolerability, whole-body distribution, and preliminary clinical activity of RAD 402 in patients with locally advanced or metastatic castration-resistant prostate cancer.

The system can be used as an irrigation option for ureteroscopy, cystoscopy, percutaneous nephrolithotomy, and benign prostatic hyperplasia procedures.

Andrew J. Armstrong, MD, MS, highlights updated recommendations from the Prostate Cancer Working Group 4.

A comprehensive guide to the key regulatory decisions and conferences slated for April-June of 2026.

In this episode of The UroOnc Minute, host Adam B. Weiner, MD, is joined by Veeru Kasivisvanathan, MBBS, MSc, PhD, FRCS, to discuss the role of biparametric vs multiparametric MRI for prostate cancer detection.

Kuang and the AACU assert that although the clinical dialogue should begin between the ages of 45 and 60, dialogue alone cannot solve the crisis without the infrastructure to support it.

This episode reflects a broader shift in the field: a move toward diagnostics that are not only more accurate, but also more human-centered.

The company remains on track to submit a supplemental Biologics License Application in the fourth quarter of 2026.

The 5-factor model aims to refine treatment decision-making by stratifying patients into 3 clinically actionable subgroups.

The label update permits thawing of nadofaragene in a 25 °C water bath over approximately 25 minutes.

Findings from a systematic review suggest that increased fluid intake, dietary modification, and selected pharmacologic therapies may reduce recurrence of kidney stones in adults.

The European Commission is expected to have a final decision on the application in the second quarter of 2026.

Two new analyses from the ASPIRE trial showed lower health care consumption events and reduced follow-up costs with the SURE procedure vs URS, with RSV emerging as a key predictor of long-term utilization.

The results highlight the complexity of secondary prevention in stone disease.

The NCCN now assigns a Category 2A recommendation for nadofaragene in patients with high-risk BCG-unresponsive NMIBC with papillary tumors without CIS.